Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Bioventus Q3 2026 Results: Net Income $5.99M, Up 89.8% YoY

Bioventus Inc. filed its Q3 2026 10-Q reporting on the period ended September 26, 2026, noting 68,474,219 shares of Class A common stock outstanding. The company is currently undergoing a strategic alternatives review process while managing risks related to debt covenants under its 2025 Credit Agreement and potential FDA reclassification of its HA products.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue142.4138.7
Gross profit97.194.2
Profit before tax6.24.7
Net income6.03.2
EPS (diluted, $ a share)$0.08$0.05

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+89.8%
Revenue, year on year+2.7%
Gross margin68.2%
Operating margin6.8%
Source

10-Q filed with the SEC, NASDAQ: BVS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Bioventus Inc.: key numbers

Share price
$10.46Close, Nov 16
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Bioventus Inc.

All →
4:13 PM ET 8-K
Financial Results

Bioventus Financial Results

Bioventus reported Q3 2026 worldwide revenue of $142.4 million, a 3% increase driven primarily by growth in its Pain Treatments business. The company achieved GAAP net income of $6.0 million and improved its diluted EPS to $0.08, while continuing to review potential strategic alternatives to maximize shareholder value.

Term
Q3 2026

“Bioventus delivered solid third-quarter results demonstrated by strong gross margin, operating cash flow and Adjusted EBITDA. We are encouraged by the underlying momentum across our key growth drivers and remain confident in our strategy, our portfolio and our ability to build Bioventus into a leading medtech company that delivers significant value for our shareholders, customers and employees.”

Rob Claypoole, Bioventus President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.